Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

Patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) have an aggressive disease course. This study aimed to describe real-world treatment patterns among patients with BRCA-positive mCRPC.

Materials and methods

De-identified electronic health record data from the Flatiron Health-Foundation Medicine Inc. Metastatic Prostate Cancer Clinico-Genomic Database (January 01, 2011 to June 30, 2022) were used to select patients with BRCA-positive mCRPC initiating first-line (1L) therapy with an oncologist-defined advanced line of therapy (LOT) or androgen deprivation therapy (ADT) monotherapy. Treatment sequences and reasons for censoring were described in 1L, and among patients who initiated a second-line (2L) therapy.

Results

A total o

SUBMITTER: Bilen MA 

PROVIDER: S-EPMC11783294 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature